MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.51
+0.17
+2.68%
Closed 16:00 09/25 EDT
OPEN
6.39
PREV CLOSE
6.34
HIGH
6.65
LOW
6.32
VOLUME
34.42K
TURNOVER
--
52 WEEK HIGH
27.90
52 WEEK LOW
3.320
MARKET CAP
32.94M
P/E (TTM)
-0.3685
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins
Was the recent market volatility just a fake out? After notching an all-time high on September 2, fears related to overheated valuations spurred a rapid correction, marking the first material correction of the current bull market. However, this doesn’t mean the bears have been vindicated, so says Wells
TipRanks · 09/18 15:31
Marinus Pharmaceuticals, Plus Therapeutics among healthcare gainers, Nano-X Imaging, Vaxart lead losers
Gainers: Marinus Pharmaceuticals (MRNS) +83%, Plus Therapeutics (PSTV) +24%, Inovio Pharmaceuticals (INO) +21%, Arbutus Biopharma ABUS +15%, Bellicum Pharmaceuticals (BLCM) +15%.Losers: Nano-X Imaging (NNOX) -24%, Vaxart (VXRT) -14%, Cassava Sciences (SAVA) -14%, 89bio, Inc. (ETNB) -12%, Replimune Group, Inc. (REPL) -8%.
Seekingalpha · 09/15 15:02
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences. Conference Details:Wells Fargo 2020
GlobeNewswire · 09/02 12:30
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020Management to host conference call and webcast today at 5 p.m. ET / 2
GlobeNewswire · 08/06 20:05
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to two new employees consisting of an aggregate o
GlobeNewswire · 07/31 20:08
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PTHOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for
GlobeNewswire · 07/30 20:05
Bellicum Pharma on go with mid-stage study of BPX-603 for HER2+ solid tumors
Seeking Alpha - Article · 06/15 12:52
Bellicum Pharma Reports FDA Investigational New Drug Clearance To Initiate Phase 1/2 Trial Of BPX-603 For HER2+ Solid Tumors
Benzinga · 06/15 11:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLCM. Analyze the recent business situations of Bellicum Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLCM stock price target is 17.33 with a high estimate of 25.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 9.67M
% Owned: 191.14%
Shares Outstanding: 5.06M
TypeInstitutionsShares
Increased
5
8.75K
New
14
-386.64K
Decreased
6
95.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
James Brown
President/Chief Executive Officer/Director
Richard Fair
Chief Financial Officer
Atabak Mokari
Senior Vice President
Aaron Foster
Controller
David Strauss
Secretary
Shane Ward
Independent Director
James Daly
Independent Director
Stephen Davis
Independent Director
Reid Huber
Independent Director
Judith Klimovsky
Independent Director
Jon Stonehouse
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BLCM
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLCM stock methods without spending real money on the virtual paper trading platform.